Lunit and Agilent partner on AI-powered companion diagnostics

SEOUL - Lunit (KRX:328130.KQ), a prominent player in the Health Care Technology sector with a strong five-year market performance, and Agilent Technologies Inc. (NYSE:A) announced Monday a nonexclusive collaboration to develop artificial intelligence-based companion diagnostic solutions for biomarker testing.

The partnership will combine Lunit’s AI algorithms with Agilent’s tissue-based diagnostic assays to create tools designed to enhance diagnosis accuracy and measure therapeutic efficacy. Initial efforts will focus on developing AI-powered assays for use in research and clinical trials. According to InvestingPro data, while Lunit currently operates with moderate debt levels, analysts anticipate sales growth in the current year, suggesting potential market expansion opportunities.

According to the companies, the joint solutions will support pharmaceutical firms in companion diagnostic product development by improving biomarker testing precision.

"Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation," said Brandon Suh, CEO of Lunit, in the press release announcing the collaboration.

Nina Green, vice-president and general manager of Agilent’s Clinical Diagnostics Division, stated that the partnership aims to "deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide."

The companies indicated that their collaboration will initially focus on evaluating biomarkers critical for developing new pharmaceutical therapies.

Lunit, founded in 2013, develops AI solutions for medical imaging and biomarker analysis, while Agilent is established in life sciences, diagnostics, and applied chemical markets.

The announcement was made in a company press release, with no financial details of the agreement disclosed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.